SavedAdd your journal

Journals / Turkish Journal of Gastroenterology / 2020 / Cilt: 31 - Sayı: 12

Two decades of research on autoimmune liver disease in Turkey

Nurhan DEMİR
Nazim EKIN
Murat TORGUTALP
Staffan WAHLIN
Cumali EFE
Pages
877–882
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Most papers (75%) werereported from 5 centers; 9 papers (20%) were published in journals with an impact factor of 3 or higher.Conclusion: The overall number and quality of AILD-related papers in Turkey are unexpectedly low, although a number of papers have receivedconsiderable international recognition.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) are the 3 mainautoimmune liver diseases (AILDs).
📊
Key Findings & Data:To determine the scientific status, we performed a scientometric analysis of AILD-related original articles that originated from Turkey.Materials and Methods: We searched the Web of Science database, the Science Citation Index Expanded (SCI-E), and the Social Sciences Citation Index (SSCI) by using the keywords “autoimmune hepatitis,” “primary biliary cholangitis/primary biliary cirrhosis,” and “primary sclerosingcholangitis” in conjunction with “Turkey.” A scientometric analysis was done on the search results.Results: We identified 117 AILD-related papers that were published in Turkey from 1997 to 2019.
💡
Conclusion & Impact:Most papers (75%) werereported from 5 centers; 9 papers (20%) were published in journals with an impact factor of 3 or higher.Conclusion: The overall number and quality of AILD-related papers in Turkey are unexpectedly low, although a number of papers have receivedconsiderable international recognition.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

Background/Aims: Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) are the 3 mainautoimmune liver diseases (AILDs). The epidemiology of AILD in Turkey is not known. To determine the scientific status, we performed a scientometric analysis of AILD-related original articles that originated from Turkey.Materials and Methods: We searched the Web of Science database, the Science Citation Index Expanded (SCI-E), and the Social Sciences Citation Index (SSCI) by using the keywords “autoimmune hepatitis,” “primary biliary cholangitis/primary biliary cirrhosis,” and “primary sclerosingcholangitis” in conjunction with “Turkey.” A scientometric analysis was done on the search results.Results: We identified 117 AILD-related papers that were published in Turkey from 1997 to 2019. Among these, 70 case reports, letters, andreviews and 2 original articles that were not cited in SCI-E/SSCI were excluded. The remaining 45 original articles were further analyzed. Thesestudies were related to AIH (n=22), PBC (n=7), PSC (n=9), PBC-AIH overlap (n=5), and others (n=2). Four of the publications originated in pediatric settings; 9 of 45 papers were published from 1997 to 2008 and 36 papers were published from 2009 to 2019. Most papers (75%) werereported from 5 centers; 9 papers (20%) were published in journals with an impact factor of 3 or higher.Conclusion: The overall number and quality of AILD-related papers in Turkey are unexpectedly low, although a number of papers have receivedconsiderable international recognition. More epidemiologic, prospective, and multicenter research projects are warranted to advance AILDknowledge and to produce high-quality research from Turkey

🔖

Cite This Article

DEMİR, N., EKIN, N., TORGUTALP, M., WAHLIN, S., EFE, C. (2020). Two decades of research on autoimmune liver disease in Turkey. Turkish Journal of Gastroenterology, Cilt: 31 - Sayı: 12, 877–882. https://ajindex.com/articles/408694

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Vierling JM. Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management. Clin Gastroenterol Hepatol 2015; 13: 2088- 108
  2. Younossi ZM, Bernstein D, Shiffman ML, et al. Diagnosis and Management of Primary Biliary Cholangitis. Am J Gastroenterol 2019; 114: 48-63
  3. Lindor KD, Kowdley KV, Harrison ME. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol 2015; 110: 646-59
  4. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213
  5. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56: 1181-8
  6. Jepsen P, Grønbæk L, Vilstrup H. Worldwide Incidence of Autoimmune Liver Disease. Dig Dis 2015; 33: 2-12
  7. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675-88
  8. Tabak F, Yurdaydın C, Kaymakoğlu S, et al. Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. Turk J Gastroenterol 2017; 28: 73-83
  9. Kaymakoğlu S, Köksal İ, Tabak F, et al. Recommendation for treatment of hepatitis C virus infection. Turk J Gastroenterol 2017; 28: 94-100
  10. Rezaee Zavareh MS, Alavian SM. Ten-year analysis of hepatitis-related papers in the Middle East: a web of science-based scientometric study. Turk J Gastroenterol 2017; 28: 20-5
  11. Kaya E, Yılmaz Y. Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turk J Gastroenterol 2019; 30: 865- 71
  12. Kaymakoglu S, Cakaloglu Y, Demir K, et al. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol 1998; 28: 78-83
  13. Efe C, Ozaslan E, Wahlin S, et al. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. Liver Int 2013; 33: 190-6
  14. Purnak T, Efe C, Kav T, Wahlin S, Ozaslan E. Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis. Dig Dis Sci 2017; 62: 2900-2907
  15. Efe C, Hagström H, Ytting H, et al. Efficacy and Safety of My cophenolate Mofetil and Tacrolimus as Second-line Therapy for Pa tients with Autoimmune Hepatitis. Clin Gastroenterol Hepatol. Clin Gastroenterol Hepatol 2017; 15: 1950-6
  16. Kuzu UB, Öztaş E, Turhan N, et al. Clinical and histological fea tures of idiosyncratic liver injury: D